A5008445985- Prenatal Screening and Diagnostics
- Ectopic Pregnancy Diagnosis and Management
- Maternal and fetal healthcare
- Gynecological conditions and treatments
- Pregnancy and preeclampsia studies
- Fetal and Pediatric Neurological Disorders
- Assisted Reproductive Technology and Twin Pregnancy
- Endometrial and Cervical Cancer Treatments
- Preterm Birth and Chorioamnionitis
- Genomic variations and chromosomal abnormalities
- Maternal and Perinatal Health Interventions
- Congenital Anomalies and Fetal Surgery
- Gestational Trophoblastic Disease Studies
- Congenital Diaphragmatic Hernia Studies
- Congenital Heart Disease Studies
- Uterine Myomas and Treatments
- Pregnancy-related medical research
- Cancer Genomics and Diagnostics
- Parvovirus B19 Infection Studies
- Gestational Diabetes Research and Management
- Congenital heart defects research
- Birth, Development, and Health
- Urological Disorders and Treatments
- Reproductive System and Pregnancy
- Cervical Cancer and HPV Research
Albert Einstein College of Medicine
2016-2025
Montefiore Medical Center
2016-2025
Society for Maternal-Fetal Medicine
2024
Sher-e-Kashmir University of Agricultural Sciences and Technology of Kashmir
2024
Montefiore Health System
2024
University of California, San Francisco
2022
Natera (United States)
2022
Accreditation Council for Graduate Medical Education
2020
Duke University
2020
Stanford University
2020
BackgroundHistorically, prenatal screening has focused primarily on the detection of fetal aneuploidies. Cell-free DNA now enables noninvasive for subchromosomal copy number variants, including 22q11.2 deletion syndrome (or DiGeorge syndrome), which is most common microdeletion and a leading cause congenital heart defects neurodevelopmental delay. Although smaller studies have demonstrated feasibility syndrome, large cohort with confirmatory postnatal testing to assess test performance not...
Cell-free DNA noninvasive prenatal screening for trisomies 21, 18, and 13 has been rapidly adopted into clinical practice. However, previous studies are limited by a lack of follow-up genetic testing to confirm the outcomes accurately assess test performance, particularly in women at low risk aneuploidy.To measure compare performance cell-free between high aneuploidy large, prospective cohort with confirmation results STUDY DESIGN: This was multicenter observational study 21 centers 6...
The clinical implications of nonreportable cell-free DNA screening results are uncertain, but such may indicate poor placental implantation in some cases and be associated with adverse obstetrical perinatal outcomes.This study aimed to assess the outcomes pregnancies a cohort patients complete genetic was prespecified secondary analysis multicenter prospective observational prenatal for fetal aneuploidy 22q11.2 deletion syndrome. Participants who underwent from April 2015 through January...
To determine the effect of removal tube on ovarian function we studied 52 artificial reproduction technology cycles in 26 women before and after undergoing laparoscopic salpingectomy for ectopic pregnancy. Ovarian response was measured by duration quantity human menopausal gonadotrophins used cycle, pre-ovulatory concentrations oestradiol, number oocytes retrieved, quality embryos. All parameters were compared between carried out as well affected unaffected sides. Our findings show no...
The objective of the study was to compare 3-dimensional power Doppler (3DPD) uteroplacental circulation space (UPCS) in first trimester between women who develop preeclampsia (PEC) and those do not assess 3DPD method as a screening tool for PEC.This prospective observational singleton pregnancies at 10 weeks 4 days 13 6 days. indices, vascularization index (VI), flow (FI), (VFI), were determined on UPSC sphere biopsy with virtual organ computer-aided analysis (VOCAL) program.Of 277 enrolled,...
Abstract Objective To evaluate nuchal translucency measurement quality assurance techniques in a large‐scale study. Methods From 1999 to 2001, unselected patients with singleton gestations between 10 + 3 weeks and 13 6 were recruited from 15 centers. Sonographic was performed by trained technicians. Four levels of employed: (1) standardized protocol utilized each sonographer; (2) local‐image review second (3) central‐image scoring single physician; (4) epidemiological monitoring all accepted...
The efficacy of treating cesarean scar pregnancies and cervical with the Cook® ripening balloon catheter, in a multicenter office‐based setting is reported. Thirty‐eight women were treated. Insertion catheter was performed under real‐time ultrasound guidance. Patients received adjuvant systemic methotrexate, prophylactic oral antibiotics, pain medication. Serum human chorionic gonadotropin scans followed serially until resolution. Thirty‐seven patients successfully treated, requiring no...
To estimate patterns of total hCG and inhibin A levels in the late first trimester Down syndrome pregnancies, compare them with that free beta-hCG, assess screening performance these markers individually combination pregnancy-associated plasma protein-A (PAPP-A) nuchal translucency.Seventy-nine matched case-control sets maternal serum samples (each case to 5 controls) from 11 through 13 completed weeks gestation were taken sample bank First Second Trimester Evaluation Risk Consortium, a...
Arteriovenous malformations (AVMs) of the uterus have various clinical presentations. With advancement and accessibility to imaging, diagnosis lesions in association with less severe presentations is becoming more common. Contrary cases hemorrhage, management these not clear. The purpose this study was describe our experience diagnosis, long-term follow-up different uterine AVMs.The sonographic 8 diagnosed between July 2000 2003 medical center are described. Annual performed for a period at...
We studied the clinical utility of chromosomal microarray analysis (CMA) in prenatal diagnosis a setting New York City.Our center began offering CMA to pregnant women undergoing invasive diagnostic procedures for an abnormal structural finding on ultrasound, maternal age 35 years or older, elevated risk aneuploidy screening, beginning March 2012. Our first six months experience is reported.Benign familial variants were most common (16/22 fetuses). Variants uncertain significance frequent,...
To examine the ability of chorionic villus sampling (CVS) and fluorescence in situ hybridization (FISH) to detect aneuploidy before first trimester fetal reduction (FR) sonographically normal-appearing fetuses.A retrospective review 470 patients referred our unit for FR from January 2007-March 2011. Prenatal diagnosis was offered all. performed after next-day FISH results. Abnormalities were categorized by ultrasound, FISH, and/or karyotype. Sensitivity, specificity, positive predictive...
PurposeThe aim of this study was to assess the performance cell-free DNA (cfDNA) screening detect sex chromosome aneuploidies (SCAs) in an unselected obstetrical population with genetic confirmation.MethodsThis a planned secondary analysis multicenter, prospective SNP-based Microdeletion and Aneuploidy RegisTry (SMART) study. Patients receiving cfDNA results for autosomal who had confirmatory relevant chromosomal were included. Screening SCAs, including monosomy X (MX) trisomies (SCT:...